Inhalers whose patents were deemed improperly listed in the Orange Book by the Federal Trade Commission have retained market dominance with their device components. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
